# Trimas Corp: Form 10-Q for the period ended Sep 30, 2020

- Company: [Trimas Corp](/companies/trs.md) (CIK 842633)
- Form: 10-Q
- Filed: 2020-10-29
- Accepted by EDGAR: Oct 29, 2020, 11:32 ET
- Period: 2020-09-30
- Accession: 0000842633-20-000093
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/842633/000084263320000093/trs-20200930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/842633/000084263320000093/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $199.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-01 to 2020-09-30 | $581.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-07-01 to 2020-09-30 | $147.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-01 to 2020-09-30 | $446.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-07-01 to 2020-09-30 | $51.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-01 to 2020-09-30 | $135.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2020-07-01 to 2020-09-30 | $25.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-09-30 | $107.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | −$108.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | −$106.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $3.5m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $11.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-07-01 to 2020-09-30 | −$12.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-09-30 | −$14.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | −$100.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | −$103.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | −$2.32 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-30 | −$2.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-01 to 2020-09-30 | −$2.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-09-30 | −$2.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-01 to 2020-09-30 | 43,457,704 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-09-30 | 43,707,331 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | $79.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-30 | $17.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 9 months, 2020-01-01 to 2020-09-30 | $36.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-09-30 | $99.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $374.7m | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $1.08bn | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $122.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $517.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-09-30 | $558.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 81,217 characters.

*The following discussion and analysis of our financial condition contains forward-looking statements regarding industry outlook and our expectations regarding the performance of our business. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under the heading "Forward-Looking Statements," at the beginning of this report. Our actual results may differ materially from those contained in or implied by any forward-looking statements. You should read the following discussion together with the Company's reports on file with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019.*

### Introduction

We are a diversified global manufacturer and provider of products for customers primarily in the consumer products, aerospace & defense and industrial markets. Our wide range of innovative products are designed and engineered to solve application-specific challenges that our customers face. We believe our businesses share important and distinguishing characteristics, including: well-recognized and leading brand names in the focused markets we serve; innovative product technologies and features; a high-degree of customer approved processes and qualifications; established distribution networks; relatively low ongoing capital investment requirements; strong cash flow conversion and long-term growth opportunities. While the majority of our revenue is in the United States, we manufacture and supply products globally to a wide range of companies. We report our business activity in three segments: Packaging, Aerospace and Specialty Products.

In December 2019, we completed the sale of our Lamons division ("Lamons"), a manufacturer and distributor of industrial sealing, fastening and specialty products primarily used in the petrochemical and petroleum-refining industries, to two wholly-owned subsidiaries of an investment fund sponsored by First Reserve. The sale of Lamons was an important strategic step for TriMas, in streamlining our portfolio of businesses, as it significantly reduced our exposure to the oil and gas market from over 20% of net sales in 2019 to less than 2% in third quarter 2020, and allowed us to further invest in our Packaging and Aerospace segments. We received net after-tax proceeds from the sale of approximately $110.9 million in 2019, subject to certain adjustments as set forth in the Purchase Agreement which were finalized in the first quarter of 2020, resulting in a $1.8 million payment to us. The financial results of Lamons were previously reported within our Specialty Products segment. The financial position, results of operations and cash flows of Lamons are reported as discontinued operations for all periods presented through the date of disposition.

#### Key Factors Affecting Our Reported Results

Our businesses and results of operations depend upon general economic conditions. We serve customers in industries that are highly competitive, cyclical and that may be significantly impacted by changes in economic or geopolitical conditions.

In March 2020, the President of the United States declared the coronavirus ("COVID-19") outbreak a national emergency, as the World Health Organization determined it was a pandemic. In response to the COVID-19 pandemic, federal, provincial, state, county and local governments and public health organizations or authorities around the world have implemented a variety of measures intended to control the spread of the virus, including quarantines, "shelter-in-place" or "stay-at-home" and similar orders, travel restrictions, business curtailments and closures, social distancing, personal hygiene requirements, and other measures.

We have been, and continue to be, focused on making sure the working environments for our employees are safe so our operations have the ability to deliver the products needed to support efforts to mitigate the COVID-19 pandemic. Nearly all of our manufacturing sites have been deemed essential operations and remained open during the pandemic, at varying levels of capacity and efficiency, experiencing only temporary shutdowns due to country-specific government mandates or for thorough cleaning as a result of suspected COVID-19 cases. The health of our employees, and the ability of our facilities to remain operational in the current regulated environment, will be critical to our future results of operations.

Our divisions were impacted in first quarter 2020 at differing levels and times, beginning with our Asian facilities and strategic supply network, both primarily in China, in late January, followed by our European (primarily Italy) and North American facilities in February and March. We implemented new work rules and processes, which promote social distancing and increased hygiene to ensure the safety of our employees, particularly at our production facilities. These measures, while not easily quantifiable, have increased the level of production inefficiencies related to absenteeism, as well as have led to less efficient manufacturing scheduling and short-term idling of production. We expect that we will continue to operate with these protocols in place, which have impacted our third quarter and year-to-date results.

Overall, our third quarter 2020 net sales increased compared to third quarter 2019, primarily as a result of robust organic sales growth in our Packaging segment, particularly for dispensing and closure products we supply that are used in applications to fight the spread of germs, and as a result of acquisitions. These increases more than offset declines in sales in our Aerospace and Specialty Products segments, primarily related to the effects of the COVID-19 pandemic.

The most significant drivers of change in results of operations in third quarter 2020 compared with third quarter 2019, other than as impacted by demand level changes as a result of the COVID-19 pandemic, were goodwill and intangible asset impairment charges in our Aerospace segment, and the impact of our recent acquisitions.

During the third quarter of 2020, we determined there was a triggering event requiring an interim quantitative impairment assessment for goodwill and indefinite-lived intangible assets within our Aerospace segment. While third quarter operating results were below pre-pandemic projected levels, the larger driver of the triggering event was a significant reduction in the July financial projection update for the remainder of 2020 compared with prior projections, and uncertainty around the duration and magnitude of the impact of the COVID-19 pandemic on future financial results given the dependence of our Aerospace segment reporting units on future levels of air travel and new aircraft builds. We determined the carrying value of both of our Aerospace reporting units, as well as of certain trade names, exceeded the fair value, resulting in non-cash, pre-tax impairment charges of approximately $126.8 million to goodwill and $7.8 million to indefinite lived intangible assets.

The techniques used in our interim impairment tests incorporated a number of assumptions that we believe to be reasonable and to reflect the current market conditions. Assumptions in estimating future cash flows and earnings were based on Level 3 inputs under the fair value hierarchy and were primarily related to customer demand and revenue growth, and associated profitability and cash flows, all as part of an aerospace industry recovery post-pandemic. Data from aerospace publications and public companies was used to assess the reasonableness of management’s assumptions regarding the timing and extent of the industry recovery. To provide a level of sensitivity analysis, a 1% change in the discount rate would have impacted the total goodwill impairment charge by approximately $20 million, while a 0.5% change in the terminal growth rate would have impacted the total goodwill impairment charge by approximately $5 million.

Changes in future results, assumptions, and estimates from the interim impairment test may lead to an outcome where additional impairment charges would be required in future periods. Specifically, actual results may vary from management's forecasts and such variations may be material and unfavorable, thereby triggering the need for future impairment tests where the conclusions may differ in reflection of prevailing market conditions. Further, continued adverse or worsening market conditions could result in the recognition of additional impairment if we determine that the fair value of our Aerospace Fasteners reporting unit has fallen below its carrying value. Certain circumstances that could reasonably be expected to negatively affect the underlying key assumptions and impact the estimated fair value of the Company’s Aerospace Fastener reporting unit may include such items as: (i) a decrease in expected future cash flows, due to the pandemic adversely impacting the aerospace industry longer or more deeply than currently estimated, (ii) inability to achieve the sales targeted as part of the Company’s strategic growth initiatives, and (iii) inability to efficiently leverage the projected sales growth at expected margin rates.

In April 2020, we acquired the Rapak brand, including certain bag-in-box product lines and assets ("Rapak") for an aggregate amount of approximately $11.4 million. Rapak, which is reported in our Packaging segment, has three manufacturing locations in the United States. Rapak contributed approximately $4.9 million of net sales during the third quarter within our Packaging segment, although it is performing below break-even operating profit as demand for its products, particularly those used in quick service restaurant applications, has significantly declined from pre-acquisition levels in 2019 due to the impact of COVID-19.

In February 2020, we completed the acquisition of RSA Engineered Products ("RSA"), a provider of highly-engineered and proprietary components for air management systems used in critical flight applications, for an aggregate amount of approximately $83.7 million, net of cash acquired. RSA is located in Simi Valley, California and designs, engineers and manufactures highly-engineered components, including air ducting products, connectors and flexible joints, predominantly used in aerospace and defense engine bleed air, anti-icing and environmental control system applications. RSA contributed approximately $4.7 million of net sales during the third quarter within our Aerospace segment.

On a year-to-date basis, there were two additional significant drivers of year-over-year change in our results of operations. First, in the second quarter of 2020, we elected to change our accounting policy for asbestos-related defense costs from accruing for probable and reasonably estimable defense costs associated with known claims expected to settle to accruing for all future defense costs for both known and unknown claims, which we now believe can be reasonably estimated. This accounting change has been reflected as a change in accounting estimate effected by a change in accounting principle. We recorded a non-cash, pre-tax charge in second quarter 2020 for asbestos-related costs of approximately $23.4 million, which is included in selling, general and administrative expenses.

In addition, during the second quarter and third quarters of 2020, we undertook certain realignment actions, primarily in our Aerospace and Specialty Products segments, in response to reduced end market demand following the outbreak of COVID-19. We recorded non-cash charges of approximately $13.2 million in second quarter 2020 related to inventory reductions, primarily as a result of a strategic decision in our Arrow Engine division to streamline its product line offering. We also recorded charges of approximately $2.3 million related to certain production equipment removed from service given reduced demand levels. In addition, we reduced our employment levels given lower customer demand, incurring approximately $3.6 million in severance charges.

#### Additional Key Risks that May Affect Our Reported Results

The COVID-19 pandemic impacted our third quarter results, and we expect it will continue to impact us in the future at varying degrees. We expect the robust customer demand for our Packaging segment's dispensing pumps and closure products used in personal care and home care applications that fight the spread of germs will continue. We are actively collaborating with our customers and strategic supply partners to manage production capacity and supply chain availability as efficiently as possible. We believe industrial demand in North America will continue to be lower than in 2019, and we are uncertain how demand will be impacted as many of the shelter-in-place orders are adjusted or lifted, particularly in North America, where orders for our industrial cylinders, for example, are heavily influenced by the levels of construction and HVAC activity, which has yet to occur at historical levels during 2020. We expect the aerospace market to experience the most severe dislocation going forward. With the current travel restrictions and significant drop in passenger miles, aircraft manufacturers have now significantly slowed production, and since late second quarter we have experienced a significant drop in aerospace-related sales compared to prior year levels. We expect this trend to continue for the foreseeable future.

We have executed realignment actions in the second and third quarter of 2020, primarily in our Aerospace and Specialty Products segments, to protect against the uncertain end market demand. We will continue to assess further actions if required. However, as a result of the pandemic's impact on global economic activity, and the continued potential impact to our future results of operations, as well as to TriMas' market capitalization, we may record additional cash and non-cash charges related to incremental realignment actions, as well as for uncollectible customer account balances, excess inventory and idle production equipment.

Despite the potential decline in future demand levels and results of operations as a result of the COVID-19 pandemic, at present, we believe our capital structure is in a solid position, and we have ample cash and available liquidity under our revolving credit facility sufficient to meet our debt service obligations, capital expenditure requirements and other short-term and long-term obligations for the foreseeable future.

The extent of the COVID-19 pandemic's effect on our operational and financial performance will depend in large part on future developments, which cannot be predicted with confidence at this time. Future developments include the duration, scope and severity of the pandemic, the actions taken to contain or mitigate its impact, and the resumption of widespread economic activity. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, we are unable to predict with any confidence the likely impact of the COVID-19 pandemic on our future operations.

Beyond the unique risks presented by the COVID-19 pandemic, other critical factors affecting our ability to succeed include: our ability to create organic growth through product development, cross-selling and extending product-line offerings, and our ability to quickly and cost-effectively introduce and successfully launch new products; our ability to acquire and integrate companies or products that supplement existing product lines, add new distribution channels or customers, expand our geographic coverage or enable better absorption of overhead costs; our ability to manage our cost structure more efficiently via supply base management, internal sourcing and/or purchasing of materials, selective outsourcing and/or purchasing of support functions, working capital management, and greater leverage of our administrative functions.

Our overall business does not experience significant seasonal fluctuation, other than our fourth quarter, which has tended to be the lowest net sales quarter of the year due to holiday shutdowns at certain customers or other customers deferring capital spending to the following year. Given the short-cycle nature of most of our businesses, we do not consider sales order backlog to be a material factor. A growing amount of our sales is derived from international sources, which exposes us to certain risks, including currency risks.

We are sensitive to price movements in our raw materials supply base. Our largest raw material purchases are for resins (such as polypropylene and polyethylene), steel, aluminum and other oil and metal-based purchased components. While material cost changes did not have a significant impact in the nine months ended September 30, 2020 compared with the nine months ended September 30, 2019, there has been some volatility over the past two years as a direct and indirect result of foreign trade policy, where tariffs on certain of our commodity-based products sourced from Asia have been instituted, and certain North American suppliers have opportunistically increased their prices. As needed, we have taken actions, and will continue to take actions, to mitigate such increases, including implementing commercial pricing adjustments, resourcing to alternate suppliers and insourcing of previously sourced products to better leverage our global manufacturing footprint. Although we believe we are generally able to mitigate the impact of higher commodity costs, we may experience additional material costs and disruptions in supply in the future and may not be able to pass along higher costs to our customers in the form of price increases or otherwise mitigate the impacts to our operating results.

Although we have escalator/de-escalator clauses in commercial contracts with certain of our customers, or can modify prices based on market conditions to recover higher costs, we cannot be assured of full cost recovery in the open market.

Our Arrow Engine business in our Specialty Products segment is sensitive to the demand for natural gas and crude oil in North America. For example, demand for engine, pump jack and compressor products are impacted by active oil and gas rig counts and wellhead investment activities. Separately, oil-based commodity costs are a significant driver of raw materials and purchased components used within our Packaging segment.

Each year, as a core tenet of the TBM, our businesses target cost savings from Kaizen and continuous improvement initiatives in an effort to reduce, or otherwise offset, the impact of increased input and conversion costs through increased throughput and yield rates, with a goal of at least covering inflationary and market cost increases. In addition, we continuously review our operating cost structures to ensure alignment with current market demand.

We continue to evaluate alternatives to redeploy the cash generated by our businesses, one of which includes returning capital to our shareholders. In first quarter 2020, our Board of Directors increased the authorization of share repurchases to a cumulative amount of $250 million. In the three and nine months ended September 30, 2020, we purchased 188,028 and 1,441,678 shares of our outstanding common stock for approximately $4.5 million and $36.0 million, respectively. During the three and nine months ended September 30, 2019, we purchased 196,128 and 723,528 shares of our outstanding common stock for approximately $5.7 million and $21.1 million, respectively.

As of September 30, 2020, we have approximately $165.1 million remaining under the repurchase authorization. We will continue to evaluate opportunities to return capital to shareholders through the purchase of our common stock, depending on market conditions and other factors.

### Segment Information and Supplemental Analysis

The following table summarizes financial information for our reportable segments for the three months ended September 30, 2020 and 2019 (dollars in thousands):

| Net Sales | Three months ended September 30, 2020 | As a Percentage of Net Sales | 2019 | As a Percentage of Net Sales |
| --- | ---: | ---: | ---: | ---: |
| Packaging | $135,120 | 67.7% | $105,480 | 56.0% |
| Aerospace | 39,130 | 19.6% | 50,560 | 26.8% |
| Specialty Products | 25,210 | 12.6% | 32,370 | 17.2% |
| Total | $199,460 | 100.0% | $188,410 | 100.0% |
| **Gross Profit** |  |  |  |  |
| Packaging | $40,240 | 29.8% | $29,580 | 28.0% |
| Aerospace | 6,930 | 17.7% | 13,830 | 27.4% |
| Specialty Products | 4,760 | 18.9% | 5,580 | 17.2% |
| Total | $51,930 | 26.0% | $48,990 | 26.0% |
| **Selling, General and Administrative Expenses** |  |  |  |  |
| Packaging | $12,220 | 9.0% | $9,840 | 9.3% |
| Aerospace | 5,840 | 14.9% | 6,020 | 11.9% |
| Specialty Products | 1,370 | 5.4% | 1,960 | 6.1% |
| Corporate | 6,220 | N/A | 7,600 | N/A |
| **Total** | $25,650 | 12.9% | $25,420 | 13.5% |
| **Operating Profit (Loss)** |  |  |  |  |
| Packaging | $28,020 | 20.7% | $19,740 | 18.7% |
| Aerospace | (133,500) | (341.2)% | 7,810 | 15.4% |
| Specialty Products | 3,380 | 13.4% | 3,620 | 11.2% |
| Corporate | (6,220) | N/A | (7,600) | N/A |
| Total | $(108,320) | (54.3)% | $23,570 | 12.5% |
| **Depreciation** |  |  |  |  |
| Packaging | $4,490 | 3.3% | $3,980 | 3.8% |
| Aerospace | 1,640 | 4.2% | 1,570 | 3.1% |
| Specialty Products | 770 | 3.1% | 720 | 2.2% |
| Corporate | 30 | N/A | 70 | N/A |
| Total | $6,930 | 3.5% | $6,340 | 3.4% |
| **Amortization** |  |  |  |  |
| Packaging | $2,320 | 1.7% | $2,390 | 2.3% |
| Aerospace | 2,880 | 7.4% | 2,130 | 4.2% |
| Specialty Products | 110 | 0.4% | 130 | 0.4% |
| Corporate | — | N/A | — | N/A |
| Total | $5,310 | 2.7% | $4,650 | 2.5% |

32

The following table summarizes financial information for our reportable segments for the nine months ended September 30, 2020 and 2019 (dollars in thousands):

| Net Sales | Nine months ended September 30, 2020 | As a Percentage of Net Sales | 2019 | As a Percentage of Net Sales |
| --- | ---: | ---: | ---: | ---: |
| Packaging | $364,000 | 62.6% | $298,310 | 54.0% |
| Aerospace | 130,660 | 22.5% | 145,650 | 26.4% |
| Specialty Products | 87,140 | 15.0% | 108,650 | 19.7% |
| Total | $581,800 | 100.0% | $552,610 | 100.0% |
| **Gross Profit** |  |  |  |  |
| Packaging | $106,770 | 29.3% | $90,290 | 30.3% |
| Aerospace | 21,510 | 16.5% | 38,860 | 26.7% |
| Specialty Products | 7,250 | 8.3% | 20,420 | 18.8% |
| Total | $135,530 | 23.3% | $149,570 | 27.1% |
| **Selling, General and Administrative Expenses** |  |  |  |  |
| Packaging | $36,430 | 10.0% | $30,270 | 10.1% |
| Aerospace | 19,550 | 15.0% | 17,590 | 12.1% |
| Specialty Products | 6,370 | 7.3% | 6,690 | 6.2% |
| Corporate | 45,220 | N/A | 24,590 | N/A |
| **Total** | $107,570 | 18.5% | $79,140 | 14.3% |
| **Operating Profit (Loss)** |  |  |  |  |
| Packaging | $70,340 | 19.3% | $60,020 | 20.1% |
| Aerospace | (132,630) | (101.5)% | 21,270 | 14.6% |
| Specialty Products | 870 | 1.0% | 13,730 | 12.6% |
| Corporate | (45,220) | N/A | (24,590) | N/A |
| Total | $(106,640) | (18.3)% | $70,430 | 12.7% |
| **Depreciation** |  |  |  |  |
| Packaging | $13,630 | 3.7% | $11,040 | 3.7% |
| Aerospace | 5,400 | 4.1% | 4,910 | 3.4% |
| Specialty Products | 2,570 | 2.9% | 2,170 | 2.0% |
| Corporate | 100 | N/A | 210 | N/A |
| Total | $21,700 | 3.7% | $18,330 | 3.3% |
| **Amortization** |  |  |  |  |
| Packaging | $6,970 | 1.9% | $7,240 | 2.4% |
| Aerospace | 8,140 | 6.2% | 6,400 | 4.4% |
| Specialty Products | 350 | 0.4% | 390 | 0.4% |
| Corporate |  | N/A | — | N/A |
| Total | $15,460 | 2.7% | $14,030 | 2.5% |

#### Results of Operations

The principal factors impacting us during the three months ended September 30, 2020, compared with the three months ended September 30, 2019, were:

- approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges in third quarter 2020 in our Aerospace segment, primarily as a result of lower current and expected future financial results due to uncertainty around the duration and magnitude of the impact of the COVID-19 pandemic;
- increases in our Packaging segment's organic sales and related operating profit as a result of significantly higher demand, primarily for our products used in applications to help fight the spread of germs;
- reduced sales and related profit within our Specialty Products and Aerospace reportable segments, primarily as a result of the COVID-19 pandemic; and
- the impact of our recent acquisitions, primarily RSA in February 2020, and Rapak in April 2020.

### Three Months Ended September 30, 2020 Compared with Three Months Ended September 30, 2019

Overall, net sales increased approximately $11.1 million, or 5.9%, to $199.5 million for the three months ended September 30, 2020, as compared with $188.4 million in the three months ended September 30, 2019, driven by our recent acquisitions, which contributed approximately $9.6 million of inorganic sales. Organic sales, excluding the impact of currency exchange, increased approximately $0.8 million, as sales increases of $24.1 million in our Packaging segment, primarily for dispenser products used in applications that help fight the spread of germs, were mostly offset by $16.1 million lower sales in our Aerospace segment and $7.2 million in our Specialty Products segment, both primarily due to lower demand as a result of the COVID-19 pandemic. In addition, net sales increased by approximately $0.7 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the stronger U.S. dollar relative to foreign currencies.

Gross profit margin (gross profit as a percentage of sales) approximated 26.0% for each of the three month periods ended September 30, 2020 and 2019. While gross profit margin remained relatively flat, gross profit dollars increased as a result of higher sales within our Packaging segment, which was partially offset by lower gross profit in our Aerospace and Specialty Products segments as a result of lower sales levels primarily due to the COVID-19 pandemic.

Operating profit (loss) margin (operating profit as a percentage of sales) approximated (54.3)% and 12.5% for the three months ended September 30, 2020 and 2019, respectively. Operating profit (loss) decreased approximately $131.9 million to an operating loss of approximately $108.3 million in the three months ended September 30, 2020, from an operating profit of approximately $23.6 million for the three months ended September 30, 2019. This decrease was primarily a result of approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges within our Aerospace segment in the third quarter of 2020. In addition, increased operating profit in our Packaging segment, primarily due to higher sales levels, slightly more than offset decreases in operating profit in our Aerospace (excluding the impairment charges) and Specialty Products segments.

Interest expense remained flat at approximately $3.5 million for each of the three month periods ended September 30, 2020 and September 30, 2019, as we did not require significant borrowings under the revolving credit facility in either period due to ample cash on hand to fund operational needs.

Other income (expense), net decreased approximately $1.8 million, to $1.2 million of other expense, net, for the three months ended September 30, 2020, as compared to $0.6 million of other income, net for the three months ended September 30, 2019, primarily due to an increase in losses on transactions denominated in foreign currencies.

The effective income tax rate for the three months ended September 30, 2020 and 2019 was 10.7% and 26.2%, respectively. We recorded a tax benefit of approximately $12.1 million for the three months ended September 30, 2020 as compared to tax expense of approximately $5.4 million for the three months ended September 30, 2019. The third quarter 2020 effective tax rate was significantly impacted by the goodwill and intangible asset impairment charges, a portion of which was non-tax deductible. The tax benefit associated with the goodwill and intangible asset impairment charges was treated as a discrete item in determining the tax expense for the quarter.

Income (loss) from continuing operations decreased approximately $116.1 million, to a net loss of $100.9 million for the three months ended September 30, 2020, as compared to net income of $15.2 million for the three months ended September 30, 2019. The decrease was the result of a decrease in operating profit (loss) of approximately $108.3 million, a decrease in other income (expense), net, partially offset by an increase in income tax benefit (expense) of approximately $17.5 million.

See below for a discussion of operating results by segment.

***Packaging.*** Net sales increased approximately $29.6 million, or 28.1%, to $135.1 million in the three months ended September 30, 2020, as compared to $105.5 million in the three months ended September 30, 2019. Acquisition-related sales growth was approximately $4.9 million resulting from our April 2020 acquisition of Rapak. Sales of dispensing products used in beauty and personal care and home care applications that help fight the spread of germs increased by approximately $23.0 million, primarily for personal hygiene applications, as demand rose, in part, due to the COVID-19 pandemic. Sales of products used in food and beverage markets increased by approximately $3.6 million, primarily due to higher sales of beverage dispensers, including pumps and related products, in North America. Sales of products used in industrial markets decreased by approximately $2.4 million, primarily as a result of lower industrial activity as a result of the pandemic. Net sales also increased by approximately $0.7 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the stronger U.S. dollar relative to foreign currencies.

Gross profit increased approximately $10.7 million to $40.2 million, or 29.8% of sales, in the three months ended September 30, 2020, as compared to $29.6 million, or 28.0% of sales, in the three months ended September 30, 2019, primarily due to increased sales levels as well as the fact that the third quarter 2019 included approximately $1.7 million of freight and logistics costs to expedite shipments to fulfill customer demand that did not repeat in third quarter 2020. In addition, gross profit margin was unfavorably impacted as a result of Rapak generating low gross profit levels.

Selling, general and administrative expenses increased approximately $2.4 million to $12.2 million, or 9.0% of sales, in the three months ended September 30, 2020, as compared to $9.8 million, or 9.3% of sales, in the three months ended September 30, 2019, primarily due to approximately $1.3 million of higher ongoing selling, general and administrative costs associated with our acquisition as well as higher personnel-related expenses to support our sales growth initiatives.

Operating profit increased approximately $8.3 million to $28.0 million, or 20.7% of sales, in the three months ended September 30, 2020, as compared to $19.7 million, or 18.7% of sales, in the three months ended September 30, 2019, primarily due to higher sales levels, which was partially offset by higher selling, general and administrative expenses.

***Aerospace.*** Net sales for the three months ended September 30, 2020 decreased approximately $11.4 million, or 22.6%, to $39.1 million, as compared to $50.6 million in the three months ended September 30, 2019. RSA, acquired in February 2020, contributed approximately $4.7 million of sales. Sales of our fastener and machined components products declined by approximately $13.1 million and $3.0 million, respectively, both due to lower demand resulting from reduced aircraft production following the onset of the COVID-19 pandemic, with fastener sales also lower than third quarter 2019, as expected, due to the 737 Max grounding.

Gross profit decreased approximately $6.9 million to $6.9 million, or 17.7% of sales, in the three months ended September 30, 2020, from $13.8 million, or 27.4% of sales, in the three months ended September 30, 2019, due primarily to the decrease in sales levels and related lower fixed cost absorption and production inefficiencies due to the impact of the COVID-19 pandemic. Gross profit further declined by approximately $2.0 million during the three months ended September 30, 2020 due to an updated estimate of a pre-acquisition contingent liability, and by approximately $0.4 million due to realignment actions executed in responses to the pandemic, primarily related to severance as we further reduced our employment levels.

Selling, general and administrative expenses decreased approximately $0.2 million to approximately $5.8 million, or 14.9% of sales, in the three months ended September 30, 2020, as compared to $6.0 million, or 11.9% of sales, in the three months ended September 30, 2019, primarily due to cost reduction efforts to mitigate the impact of lower sales levels, partially offset by higher ongoing selling, general and administrative costs associated with our acquisition of RSA.

Operating profit (loss) decreased approximately $141.3 million to an operating loss of $133.5 million, or 341.2% of sales, in the three months ended September 30, 2020, as compared to an operating profit of $7.8 million, or 15.4% of sales, in the three months ended September 30, 2019. Operating profit and related margin decreased primarily due to approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges in the third quarter of 2020. Operating profit also declined due to lower sales levels, which resulted in lower fixed cost absorption and higher production inefficiencies as a result of the COVID-19 pandemic, the updated pre-acquisition contingent liability charge and the impact of realignment charges.

***Specialty Products.*** Net sales for the three months ended September 30, 2020 decreased approximately $7.2 million, or 22.1%, to $25.2 million, as compared to $32.4 million in the three months ended September 30, 2019. Sales of our cylinder products decreased approximately $4.5 million, due to lower demand for steel cylinders used in construction and industrial packaged gases in North America, which was partially offset by sales of cylinders used in oxygen and other medical applications. Sales of engines, compressors and related parts used in upstream oil and gas applications decreased by approximately $2.7 million, primarily as a result of lower oil-field activity in North America and continued historic low rig counts.

Gross profit decreased approximately $0.8 million to gross profit of $4.8 million, or 18.9% of sales, in the three months ended September 30, 2020, as compared to $5.6 million, or 17.2% of sales, in the three months ended September 30, 2019, due to the decrease in sales levels and related lower fixed cost absorption and production inefficiencies as a result of the pandemic.

Selling, general and administrative expenses decreased approximately $0.6 million to $1.4 million, or 5.4% of sales, in the three months ended September 30, 2020, as compared to $2.0 million, or 6.1% of sales, in the three months ended September 30, 2019, primarily due to lower employment and spending levels to align with the decline in sales levels.

Operating profit decreased approximately $0.2 million to $3.4 million, or 13.4% of sales, in the three months ended September 30, 2020, as compared to $3.6 million, or 11.2% of sales, in the three months ended September 30, 2019, primarily as a result of the impact of lower sales and related lower fixed cost absorption and production inefficiencies.

***Corporate.*** Corporate expenses consist of the following (dollars in millions):

|  | Three months ended September 30, 2020 | 2019 |
| --- | ---: | ---: |
| Corporate operating expenses | $5.1 | $5.8 |
| Non-cash stock compensation | 0.9 | 1.0 |
| Legacy expenses | 0.2 | 0.8 |
| Corporate expenses | $6.2 | $7.6 |

Corporate expenses decreased approximately $1.4 million to $6.2 million for the three months ended September 30, 2020, from $7.6 million for the three months ended September 30, 2019, primarily as a result of reduced legacy expenses following the change in our accounting policy for asbestos-related defense costs in second quarter 2020, as well as lower corporate operating expenses which have been reduced in response to the pandemic.

### Nine Months Ended September 30, 2020 Compared with Nine Months Ended September 30, 2019

Overall, net sales increased approximately $29.2 million, or 5.3%, to $581.8 million for the nine months ended September 30, 2020, as compared with $552.6 million in the nine months ended September 30, 2019, driven by our recent acquisitions, which contributed approximately $33.1 million of inorganic sales growth. Organic sales, excluding the impact of currency exchange, decreased approximately $1.2 million, as approximately $48.9 million of sales increases in our Packaging segment, primarily for products used in applications that help fight the spread of germs, were more than offset by approximately $28.6 million lower sales in our Aerospace segment and $21.5 million lower sales in our Specialty Products segment, both primarily due to lower demand as a result of the COVID-19 pandemic. In addition, net sales were lower by approximately $2.7 million due to unfavorable currency exchange, as our reported results in U.S. dollars were negatively impacted as a result of the stronger U.S. dollar relative to foreign currencies.

Gross profit margin (gross profit as a percentage of sales) approximated 23.3% and 27.1% for the nine months ended September 30, 2020 and 2019, respectively. Gross profit margin decreased, as the impact of higher sales levels was more than offset by the impact of approximately $16.4 million of realignment expenses during the nine months ended September 30, 2020, $14.3 million of which were non-cash and $2.1 million of which were cash expenses, primarily in our Aerospace and Specialty Products segments, where we executed actions to lower our cost structure in response to reduced end market demand following the outbreak of COVID-19 pandemic. In addition, we recorded approximately $2.8 million of non-cash purchase accounting charges in the nine months ended September 30, 2020 for the step-up of inventory to fair value and subsequent amortization related to our RSA and Rapak acquisitions as compared to approximately $0.3 million of such charges for our 2019 acquisitions in the nine months ended September 30, 2019. Our gross profit margin in the first nine months of 2020 was also negatively impacted by approximately $2.0 million for an updated estimate of a pre-acquisition contingent liability within our Aerospace segment, as well as lower fixed cost absorption and higher production inefficiencies due primarily to the COVID-19 pandemic.

Operating profit (loss) margin (operating profit as a percentage of sales) approximated (18.3)% and 12.7% for the nine months ended September 30, 2020 and 2019, respectively. Operating profit (loss) decreased approximately $177.1 million, or 251.4%, to $106.6 million of operating loss for the nine months ended September 30, 2020, compared to $70.4 million of operating profit for the nine months ended September 30, 2019. This decrease was primarily a result of approximately $134.6 million of non-cash goodwill and indefinite-lived intangible asset impairment charges within our Aerospace segment and an approximate $23.4 million non-cash charge due to a change in accounting policy, both in the nine months ended September 30, 2020. Operating profit further decreased due to approximately $19.1 million of realignment expenses recorded in the nine months ended September 30, 2020, of which $15.5 million were non-cash and $3.6 million were cash expenses, primarily in our Aerospace and Specialty Products segments, where we executed actions to lower our cost structure in response to reduced end market demand following the outbreak of COVID-19. Operating profit (loss) also decreased as a result of increased purchase accounting expenses and as a result of unfavorable currency exchange.

Interest expense increased approximately $0.8 million, to $11.3 million, for the nine months ended September 30, 2020, as compared to $10.5 million for the nine months ended September 30, 2019, primarily as a result of increased weighted average borrowings from approximately $335.3 million during the nine months ended September 30, 2019 to approximately $387.7 million during the nine months ended September 30, 2020. We drew $150 million on our revolving credit facility in first quarter 2020 to ensure availability of cash on hand, but subsequently repaid this amount late in second quarter 2020.

Other income (expense), net decreased approximately $1.4 million, to $0.2 million of other expense for the nine months ended September 30, 2020, from $1.3 million of other income, net for the nine months ended September 30, 2019, primarily due to a year-over-year increase in losses on transactions denominated in foreign currencies.

The effective income tax rate for the nine months ended September 30, 2020 and 2019 was 12.4% and 20.8%, respectively. We recorded a tax benefit of approximately $14.6 million for the nine months ended September 30, 2020 as compared to tax expense of approximately $12.7 million for the nine months ended September 30, 2019. The effective tax rate for the nine months ended September 30, 2020 was impacted by a decrease in profitability resulting from various one-time charges, including a change in the Company’s accounting policy for asbestos-related defense costs and impairment of goodwill and indefinite-lived intangible assets. These charges were treated as discrete items in determining tax expense for the nine months ended September 30, 2020. In addition, we recognized discrete items that occurred during the first nine months of 2019, including the reversal of uncertain tax benefits for which the statute of limitations expired, excess tax benefits related to share based compensation that vested in 2019, and a reduction in deferred tax liabilities resulting from the implementation of state tax planning initiatives.

Income (loss) from continuing operations decreased by approximately $152.0 million, to a loss of $103.5 million for the nine months ended September 30, 2020, compared to income of $48.5 million for the nine months ended September 30, 2019. The decrease was the result of a decrease in operating profit (loss) of approximately $177.1 million, a decrease in other income (expense), net and an increase in interest expense, partially offset by an increase in income tax benefit (expense) of approximately $27.3 million.

See below for a discussion of operating results by segment.

***Packaging.*** Net sales increased approximately $65.7 million, or 22.0%, to $364.0 million in the nine months ended September 30, 2020, as compared to $298.3 million in the nine months ended September 30, 2019. Acquisition-related growth was approximately $19.5 million, comprised of approximately $9.4 million of sales from our April 2020 acquisition of Rapak as well as $10.1 million of January through April 2020 sales for Taplast, which was acquired in late April 2019. Sales of dispensing products used in beauty and personal care and home care applications increased by approximately $33.7 million, primarily as demand increased for personal hygiene applications due to heightened awareness of reducing the spread of germs following the onset of the COVID-19 pandemic. Sales of products used in food and beverage markets increased by approximately $11.5 million, primarily due to higher sales of beverage dispensers, including pumps and related products, in North America. Sales of products used in industrial markets increased by approximately $1.4 million, primarily due to higher demand within North America, some of which we believe is attributable to higher sales of products used in the transportation of bulk sanitizer and industrial cleaning solutions. These increases were partially offset by approximately $2.7 million of unfavorable currency exchange, as our reported results in U.S. dollars were negatively impacted as a result of the stronger U.S. dollar relative to foreign currencies.

Packaging's gross profit increased approximately $16.5 million to $106.8 million, or 29.3% of sales, in the nine months ended September 30, 2020, as compared to $90.3 million, or 30.3% of sales, in the nine months ended September 30, 2019, primarily due to increased sales levels. In addition, the first three quarters of 2019 included approximately $1.7 million of freight and logistics costs to expedite shipments to fulfill customer demand which did not repeat in 2020. These increases were partially offset by approximately $0.9 million in non-cash realignment costs during the first three quarters of 2020 primarily related to the disposal of certain equipment which was taken out of service and approximately $0.8 million for a purchase accounting non-cash charge related to the step-up of Rapak's inventory to fair value and subsequent amortization. Gross profit margin was lower than third quarter 2019 due to a less favorable product sales mix and generally lower production efficiencies, as well as Rapak generating low gross profit at current demand levels, all as a result of the impacts of the COVID-19 pandemic. Gross profit and margin were also impacted by approximately $0.7 million of unfavorable currency exchange, as our reported results in U.S. dollars were negatively impacted as a result of the stronger U.S. dollar relative to foreign currencies.

Packaging's selling, general and administrative expenses increased approximately $6.2 million to $36.4 million, or 10.0% of sales, in the nine months ended September 30, 2020, as compared to $30.3 million, or 10.1% of sales, in the nine months ended September 30, 2019, as we incurred approximately $1.4 million in charges associated with our realignment actions, primarily for severance in the nine months ended September 30, 2020. We also incurred approximately $2.9 million of higher ongoing selling, general and administrative costs associated with our acquisitions, as well as recorded higher personnel-related expenses supporting the higher demand for our products. This increase was partially offset by an approximate $0.8 million non-cash charge during the nine months ended September 30, 2019 related to the write-off of the trade name acquired in the Plastic Srl acquisition that was not used.

Packaging's operating profit increased approximately $10.3 million to $70.3 million, or 19.3% of sales, in the nine months ended September 30, 2020, as compared to $60.0 million, or 20.1% of sales, in the nine months ended September 30, 2019, as a result of increased sales, which was partially offset by realignment charges taken during 2020, the recognition of the purchase accounting adjustment related to Rapak's inventory step-up to fair value and subsequent amortization, a less favorable product sales mix, production inefficiencies as a result of COVID-19 and higher selling, general and administrative expenses.

***Aerospace.*** Net sales for the nine months ended September 30, 2020 decreased approximately $15.0 million, or 10.3%, to $130.7 million, as compared to $145.7 million in the nine months ended September 30, 2019. The February 2020 acquisition of RSA contributed approximately $13.5 million of sales. Sales of our fastener and machined components products declined by approximately $20.9 million and $7.6 million, respectively, both due to lower demand resulting from current and expected future reduced air travel due to the COVID-19 pandemic, with fastener sales also lower than the first half of 2019, as expected, due to the 737 Max grounding.

Gross profit within Aerospace decreased approximately $17.4 million to $21.5 million, or 16.5% of sales, in the nine months ended September 30, 2020, from $38.9 million, or 26.7% of sales, in the nine months ended September 30, 2019, due in part to the decrease in sales levels and related lower fixed cost absorption and production inefficiencies due to the impact of the COVID-19 pandemic. In the second and third quarters of 2020, we undertook certain realignment actions to protect against uncertain end market demand related to the COVID-19 pandemic, resulting in charges of approximately $4.2 million related to inventory reductions, $2.1 million related to severance as we reduced our manufacturing employment levels and $0.3 million related to production equipment removed from service given current demand levels. In addition, we recorded an approximate $2.0 million purchase accounting non-cash charge related to the step-up of RSA's inventory to fair value and subsequent amortization during the first half of 2020 as well as approximately $2.0 million for an update to a pre-acquisition contingent liability.

Selling, general and administrative expenses increased approximately $2.0 million to $19.6 million, or 15.0% of sales, in the nine months ended September 30, 2020, as compared to $17.6 million, or 12.1% of sales, in the nine months ended September 30, 2019, primarily due to ongoing costs of RSA and approximately $0.6 million of realignment expenses incurred in the nine months ended September 30, 2020. The increase was partially offset by cost reduction efforts to mitigate the impact of lower sales levels.

Operating profit (loss) within Aerospace decreased approximately $153.9 million to an operating loss of $132.6 million, or 101.5% of sales, in the nine months ended September 30, 2020, as compared to an operating profit of $21.3 million, or 14.6% of sales, in the nine months ended September 30, 2019. Operating profit and related margin decreased primarily due to approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges in the third quarter of 2020. Operating profit also declined due to realignment charges, as well as the impact of lower sales levels, which resulted in lower fixed cost absorption and higher production inefficiencies as a result of the COVID-19 pandemic, the recognition of the purchase accounting adjustment related to RSA's inventory step-up to fair value and subsequent amortization, higher selling, general and administrative expenses and the update of a pre-acquisition contingent liability.

***Specialty Products.*** Net sales for the nine months ended September 30, 2020 decreased approximately $21.5 million, or 19.8%, to $87.1 million, as compared to $108.7 million in the nine months ended September 30, 2019. Sales of our cylinder products decreased by approximately $16.3 million, as low demand for steel cylinders used in construction and HVAC activity in North America was partially offset by a modest increase in the sale of cylinders used for oxygen and other medical applications. Sales of engines, compressors and related parts used in upstream oil and gas applications decreased by approximately $5.2 million, primarily as a result of low oil-field activity in North America given the low price of oil.

Gross profit within Specialty Products decreased approximately $13.2 million to $7.3 million, or 8.3% of sales, in the nine months ended September 30, 2020, as compared to $20.4 million, or 18.8% of sales, in the nine months ended September 30, 2019, due in part to the decrease in sales levels and related lower fixed cost absorption and production inefficiencies due primarily to the impact of the COVID-19 pandemic. In addition, during the second quarter of 2020, we undertook certain realignment actions in response to reduced end market demand as a result of the COVID-19 pandemic, resulting in approximately $9.0 million of non-cash charges in the nine months ended September 30, 2020, primarily related to Arrow Engine streamlining its product line offering and liquidating its non-core inventory.

Selling, general and administrative expenses within Specialty Products decreased approximately $0.3 million to $6.4 million, or 7.3% of sales, in the nine months ended September 30, 2020, as compared to $6.7 million, or 6.2% of sales, in the nine months ended September 30, 2019. During the first nine months of 2020, we incurred selling, general and administrative realignment expenses of approximately $0.7 million related to severance as we reduced our employment levels, which was partially offset by reduced spending levels as a result of lower activity levels.

Operating profit within Specialty Products decreased approximately $12.9 million to $0.9 million, or 1.0% of sales, in the nine months ended September 30, 2020, as compared to $13.7 million of operating profit, or 12.6% of sales, in the nine months ended September 30, 2019, primarily as a result of the 2020 realignment actions, as well as due to the impact of lower sales and related lower fixed cost absorption and production inefficiencies.

***Corporate.*** Corporate expenses, net consist of the following (dollars in millions):

|  | Nine months ended September 30, 2020 | 2019 |
| --- | ---: | ---: |
| Corporate operating expenses | $16.1 | $17.6 |
| Non-cash stock compensation | 5.6 | 3.9 |
| Legacy expenses | 23.5 | 3.1 |
| Corporate expenses | $45.2 | $24.6 |

Corporate expenses increased approximately $20.6 million to $45.2 million for the nine months ended September 30, 2020, from $24.6 million for the nine months ended September 30, 2019, primarily as a result of the $23.4 million non-cash charge recorded in second quarter 2020 due to the change of our accounting policy for asbestos-related defense costs from accruing for probable and reasonably estimable defense costs associated with known claims expected to settle to accrue for all future defense costs for both known and unknown claims, which we now believe can be reasonably estimated. Non-cash stock compensation expense increased due to the timing and nature of equity awards in 2020 compared with 2019, the impact of which was mostly offset by lower corporate operating expenses and the favorable resolution of legacy matters during the nine months ended September 30, 2020.

### Liquidity and Capital Resources

#### Cash Flows

Cash flows provided by operating activities were approximately $79.1 million for the nine months ended September 30, 2020, as compared to approximately $60.6 million for the nine months ended September 30, 2019. Significant changes in cash flows provided by operating activities and the reasons for such changes were as follows:

- For the nine months ended September 30, 2020, the Company generated approximately $82.7 million of cash, based on the reported net loss of approximately $103.5 million and after considering the effects of non-cash items related to depreciation, amortization, loss on dispositions of assets, changes in deferred income taxes, stock-based compensation, asbestos-related change in liability estimate, impairment of goodwill and indefinite-lived intangible assets and other operating activities. For the nine months ended September 30, 2019, the Company generated approximately $91.5 million in cash flows based on the reported net income from continuing operations of approximately $48.5 million and after considering the effects of similar non-cash items.
- Increases in accounts receivable resulted in a use of cash of approximately $6.2 million and $8.4 million for the nine months ended September 30, 2020 and 2019, respectively. The increased use of cash for each of the nine month periods is due primarily to the timing of sales and collection of cash related thereto within the periods. Days sales outstanding of receivables decreased by approximately three days compared to third quarter 2019.
- We decreased our investment in inventory by approximately $4.5 million for the nine months ended September 30, 2020, while we increased our investment in inventory by approximately $0.6 million for the nine months ended September 30, 2019. Our days sales in inventory decreased by approximately 12 days through the nine months ended September 30, 2020 and decreased approximately three days as compared to third quarter 2019, primarily as a result of the strategic decision in our Arrow Engine division to streamline its product line offering. We continue to moderate inventory levels in line with sales levels.
- Decreases in prepaid expenses and other assets resulted in a source of cash of approximately $5.5 million for the nine months ended September 30, 2020 and of approximately $4.8 million for the nine months ended September 30, 2019. These changes were primarily a result of the timing of payments made for income taxes and certain operating expenses.
- Decreases in accounts payable and accrued liabilities resulted in a use of cash of approximately $7.4 million and $26.8 million for the nine months ended September 30, 2020 and 2019, respectively, primarily as a result of the timing of payments made to suppliers and the mix of vendors and related terms. Days accounts payable on hand decreased by approximately six days in 2020 as compared with the comparable 2019 period, primarily as we paid certain key Packaging vendors more quickly in 2020 to ensure our orders remained a top priority for them given our robust demand levels and minimal available capacity in the marketplace.

Net cash used for investing activities of continuing operations for the nine months ended September 30, 2020 and 2019 was approximately $110.9 million and $89.1 million, respectively. During the first nine months of 2020, we paid approximately $95.2 million, net of cash acquired, to acquire RSA and Rapak. We incurred approximately $17.7 million in capital expenditures, as we continued our investment in growth, capacity and productivity-related capital projects. We also received proceeds from disposition of business, property and equipment of approximately $1.9 million. During the first nine months of 2019, we incurred approximately $22.0 million in capital expenditures and paid approximately $67.0 million, net of cash acquired, to acquire Plastic Srl and Taplast.

Net cash used for financing activities for the nine months ended September 30, 2020 was approximately $40.9 million, while net cash used for financing activities was $23.9 million for the nine months ended September 30, 2019. During the first nine months of 2020, we made net repayments of approximately $2.3 million on our revolving credit facilities. We also purchased approximately $36.0 million of outstanding common stock and used a net cash amount of approximately $2.6 million related to our stock compensation arrangements. During the first nine months of 2019, we borrowed approximately $0.5 million, net of repayments, on our revolving credit facilities. We also purchased approximately $21.1 million of outstanding common stock and used a net cash amount of approximately $3.2 million related to our stock compensation arrangements.

#### Our Debt and Other Commitments

The $300.0 million aggregate principal amount of senior notes accrue interest at a rate of 4.875% per annum, payable semi-annually in arrears on April 15 and October 15, commencing on April 15, 2018 ("Senior Notes"). The payment of principal and interest is jointly and severally guaranteed, on a senior unsecured basis by certain named subsidiaries of the Company (each a "Guarantor" and collectively the "Guarantors"). The Senior Notes are *pari passu* in right of payment with all existing and future senior indebtedness and subordinated to all existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness. For the nine months ended September 30, 2020, our consolidated subsidiaries that do not guarantee the Senior Notes represented approximately 22% of the total of guarantor and non-guarantor net sales, treating each as a consolidated group and excluding intercompany transactions between guarantor and non-guarantor subsidiaries. In addition, our non-guarantor subsidiaries represented approximately 33% and 14% of the total guarantor and non-guarantor assets and liabilities, respectively, as of September 30, 2020, treating the guarantor and non-guarantor subsidiaries each as a consolidated group and excluding intercompany transactions between such groups.

We may redeem all or part of the Senior Notes at a redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, plus a "make whole" premium.

We are party to a credit agreement ("Credit Agreement") consisting of a $300.0 million senior secured revolving credit facility, which permits borrowings denominated in specific foreign currencies, subject to a $125.0 million sub limit. The Credit Agreement matures on September 20, 2022 and is subject to interest at London Interbank Offered Rate ("LIBOR") plus 1.50%. The interest rate spread is based upon the leverage ratio, as defined, as of the most recent determination date. The Credit Agreement allows issuance of letters of credit, not to exceed $40.0 million in aggregate, against revolving credit facility commitments.

The Credit Agreement also provides for incremental revolving credit commitments in an amount not to exceed the greater of $200.0 million and an amount such that, after giving effect to such incremental commitments and the incurrence of any other indebtedness substantially simultaneously with the making of such commitments, the senior secured net leverage ratio, as defined in the Credit Agreement, is no greater than 3.00 to 1.00. The terms and conditions of any incremental revolving credit facility commitments must be no more favorable than the existing credit facility.

Amounts drawn under our revolving credit facility fluctuate daily based upon our working capital and other ordinary course needs. Availability under our revolving credit facility depends upon, among other things, compliance with our Credit Agreement's financial covenants. Our Credit Agreement contains various negative and affirmative covenants and other requirements affecting us and our subsidiaries, including the ability to, subject to certain exceptions and limitations, incur debt, liens, mergers, investments, loans, advances, guarantee obligations, acquisitions, asset dispositions, sale-leaseback transactions, hedging agreements, dividends and other restricted payments, transactions with affiliates, restrictive agreements and amendments to charters, bylaws, and other material documents. The terms of our Credit Agreement require us and our subsidiaries to meet certain restrictive financial covenants and ratios computed quarterly, including a maximum total net leverage ratio (total consolidated indebtedness plus outstanding amounts under the accounts receivable securitization facility, less the aggregate amount of certain unrestricted cash and unrestricted permitted investments, as defined, over consolidated EBITDA, as defined), a maximum senior secured net leverage ratio (total consolidated senior secured indebtedness, less the aggregate amount of certain unrestricted cash and unrestricted permitted investments, as defined, over consolidated EBITDA, as defined) and a minimum interest expense coverage ratio (consolidated EBITDA, as defined, over the sum of consolidated cash interest expense, as defined, and preferred dividends, as defined). Our permitted total net leverage ratio under the Credit Agreement is 4.00 to 1.00 as of September 30, 2020. If we were to complete an acquisition which qualifies for a Covenant Holiday Period, as defined in our Credit Agreement, then our permitted total net leverage ratio cannot exceed 4.50 to 1.00 during that period. Our actual total net leverage ratio was 1.44 to 1.00 at September 30, 2020. Our permitted senior secured net leverage ratio under the Credit Agreement is 3.50 to 1.00 as of September 30, 2020. If we were to complete an acquisition which qualifies for a Covenant Holiday Period, as defined in our Credit Agreement, then our permitted senior secured net leverage ratio cannot exceed 4.00 to 1.00 during that period. Our actual senior secured net leverage ratio was not meaningful at September 30, 2020. Our permitted interest expense coverage ratio under the Credit Agreement is 3.00 to 1.00 as of September 30, 2020. Our actual interest expense coverage ratio was 12.79 to 1.00 at September 30, 2020. At September 30, 2020, we were in compliance with our financial covenants.

The following is a reconciliation of net income, as reported, which is a GAAP measure of our operating results, to Consolidated Bank EBITDA, as defined in our Credit Agreement, for the twelve months ended September 30, 2020 (dollars in thousands). We present Consolidated Bank EBITDA to show our performance under our financial covenants.

|  | Twelve Months Ended September 30, 2020 |
| --- | ---: |
| Net income | $(65,050) |
| Bank stipulated adjustments: |  |
| Interest expense | 14,760 |
| Income tax expense | 7,590 |
| Depreciation and amortization | 49,180 |
| Impairment charges and asset write-offs | 134,600 |
| Non-cash compensation expense(1) | 7,930 |
| Other non-cash expenses or losses | 17,780 |
| Non-recurring expenses or costs(2) | 7,650 |
| Extraordinary, non-recurring or unusual gains or losses | 22,910 |
| Effects of purchase accounting adjustments | 2,110 |
| Business and asset dispositions | 930 |
| Permitted acquisitions | 2,040 |
| Permitted dispositions(3) | (40,150) |
| Consolidated Bank EBITDA, as defined | $162,280 |

|  | September 30, 2020 |  |
| --- | ---: | --- |
| Total Indebtedness, as defined | $234,340 |  |
| Consolidated Bank EBITDA, as defined | 162,280 |  |
| Total net leverage ratio | 1.44 | x |
| Covenant requirement | 4.00 | x |

|  | September 30, 2020 |  |
| --- | ---: | --- |
| Total Senior Secured Indebtedness(4) | $(65,660) |  |
| Consolidated Bank EBITDA, as defined | 162,280 |  |
| Senior secured net leverage ratio | n/m | x |
| Covenant requirement | 3.50 | x |

|  | Twelve Months Ended September 30, 2020 |
| --- | ---: |
| Interest expense | $14,760 |
| Bank stipulated adjustments: |  |
| Interest income | (700) |
| Non-cash amounts attributable to amortization of financing costs | (1,370) |
| Total Consolidated Cash Interest Expense, as defined | $12,690 |

42

|  | September 30, 2020 |  |
| --- | ---: | --- |
| Consolidated Bank EBITDA, as defined | $162,280 |  |
| Total Consolidated Cash Interest Expense, as defined | 12,690 |  |
| Actual interest expense coverage ratio | 12.79 | x |
| Covenant requirement | 3.00 | x |

(1) Non-cash compensation expenses resulting from the grant of equity awards.

(2) Non-recurring costs and expenses relating to diligence and transaction costs, purchase accounting costs, severance, relocation, restructuring and curtailment expenses.

(3) EBITDA from permitted dispositions, as defined.

(4) Senior secured indebtedness is negative at September 30, 2020 due to the deduction of certain unrestricted cash and unrestricted permitted investments as allowed under the Credit Agreement.

During the three months ended September 30, 2020, we placed approximately $10.5 million of restricted cash on deposit with a financial institution to be held as cash collateral for our outstanding letters of credit; therefore, as of September 30, 2020, we had no letters of credit issued against our revolving credit facility. At September 30, 2020, we had no amounts outstanding under our revolving credit facility and had approximately $300.0 million potentially available after giving effect to letters of credit issued and outstanding. At December 31, 2019, we had no amounts outstanding under our revolving credit facility and had approximately $283.9 million potentially available after giving effect to approximately $16.1 million of letters of credit issued and outstanding. The letters of credit are used for a variety of purposes, including support of certain operating lease agreements, vendor payment terms and other subsidiary operating activities, and to meet various states' requirements to self-insure workers' compensation claims, including incurred but not reported claims. Our borrowing capacity was not reduced by leverage restrictions contained in the Credit Agreement as of September 30, 2020 and December 31, 2019.

We rely upon our cash flow from operations and available liquidity under our revolving credit facility to fund our debt service obligations and other contractual commitments, working capital and capital expenditure requirements. At the end of each quarter, we have historically used cash on hand from our domestic and foreign subsidiaries to pay down amounts outstanding under our revolving credit facility, as applicable.

Our weighted average borrowings during the first nine months of 2020 approximated $387.7 million, compared to approximately $335.3 million during the first nine months of 2019, due to our March 2020 proactive $150 million draw on our revolving credit facility to ensure availability of cash on hand given the potential uncertainty surrounding the financial markets as a result of the COVID-19 pandemic. We repaid the $150 million during second quarter 2020.

Cash management related to our revolving credit facility is centralized. We monitor our cash position and available liquidity on a daily basis and forecast our cash needs on a weekly basis within the current quarter and on a monthly basis outside the current quarter over the remainder of the year. Our business and related cash forecasts are updated monthly.

In considering the economic uncertainty surrounding the potential business impacts from the COVID-19 pandemic with respect to our operations, supply chains, distribution channels, and end-market customers, we have taken certain defensive actions as we monitor our cash position and available liquidity. These actions have included suspending our repurchase of our common stock during second quarter 2020, borrowing on our revolving credit facility, tightening our capital expenditures, advanced monitoring of our accounts receivable balances and flexing cost structures of operations expected to be most impacted by COVID-19. Given strong cash generation and our current liquidity position, we relaxed certain of these actions in the third quarter of 2020, choosing to further invest in capital expenditures for our businesses and resume purchasing shares of common stock.

With more than half of our cash on hand as of September 30, 2020 located within the U.S., given available funding under our revolving credit facility of $300.0 million at September 30, 2020 (after consideration of the aforementioned leverage restrictions) and based on forecasted cash sources and requirements inherent in our business plans, we believe that our liquidity and capital resources, including anticipated cash flows from operations, will be sufficient to meet our debt service, capital expenditure and other short-term and long-term obligations for the foreseeable future.

We are subject to variable interest rates on our revolving credit facility. At September 30, 2020, 1-Month LIBOR approximated 0.15%. At September 30, 2020, we had no amounts outstanding on our revolving credit facility and, therefore, no variable rate-based borrowings outstanding.

In addition to our long-term debt, we have other cash commitments related to leases. We account for these lease transactions as operating leases, and annual rent expense for continuing operations related thereto approximated $7.5 million in 2019. We expect leasing will continue to be an available financing option to fund future capital expenditure requirements.

In March 2020, we announced our Board of Directors had authorized us to increase the purchase of our common stock up to $250 million in the aggregate, an increase of $100 million from the prior authorization. In the three and nine months ended September 30, 2020, we purchased 188,028 and 1,441,678 shares of our outstanding common stock for an aggregate purchase price of approximately $4.5 million and $36.0 million, respectively. Since the initial authorization through September 30, 2020 we have purchased 3,114,360 shares of our outstanding common stock for an aggregate purchase price of approximately $84.9 million. We will continue to evaluate opportunities to return capital to shareholders through the purchase of our common stock, depending on market conditions, including the potential impact of the COVID-19 pandemic, and other factors.

### Market Risk

We conduct business in various locations throughout the world and are subject to market risk due to changes in the value of foreign currencies. The functional currencies of our foreign subsidiaries are primarily the local currency in the country of domicile. We manage these operating activities at the local level and revenues and costs are generally denominated in local currencies; however, results of operations and assets and liabilities reported in U.S. dollars will fluctuate with changes in exchange rates between such local currencies and the U.S. dollar.

We use derivative financial instruments to manage currency risks associated with our procurement activities denominated in currencies other than the functional currency of our subsidiaries and the impact of currency rate volatility on our earnings. As of September 30, 2020, we were party to foreign exchange forward and swap contracts to hedge changes in foreign currency exchange rates with notional amounts of approximately $63.5 million. We also use cross-currency swap agreements to mitigate currency risks associated with the net investment in certain of our foreign subsidiaries. See Note 12, "*Derivative Instruments*," included in Part 1, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," within this quarterly report on Form 10-Q for additional information.

We are also subject to interest risk as it relates to our long-term debt. We have historically used interest rate swap agreements to fix the variable portion of our debt to manage this risk. See Note 11, "*Long-term Debt*," included in Part 1, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," within this quarterly report on Form 10-Q for additional information.

### Common Stock

TriMas is listed in the NASDAQ Global Select MarketSM. Our stock trades under the symbol "TRS."

### Credit Rating

We and certain of our outstanding debt obligations are rated by Standard & Poor's and Moody's. On June 12, 2020, Moody's affirmed a Ba3 rating to our Senior Notes, as presented in Note 11, *"Long-term Debt"* included in Part I, Item 1, *"Notes to Unaudited Consolidated Financial Statements"* within this quarterly report on Form 10-Q. Moody's also affirmed a Ba2 Corporate Family Rating and maintained its outlook as stable. On February 12, 2020, Standard & Poor's affirmed a BB- rating to our senior unsecured debt, affirmed a BB corporate credit rating and maintained its outlook as stable. If our credit ratings were to decline, our ability to access certain financial markets may become limited, our cost of borrowings may increase, the perception of us in the view of our customers, suppliers and security holders may worsen and as a result, we may be adversely affected.

### Outlook

Through the first nine months of 2020, we experienced year-over-year overall growth in sales, driven by robust organic growth in our Packaging segment and from acquisitions, which were partially offset by sales decreases in our Aerospace and Specialty Products segments. We expect these general segment trends for sales will continue through the remainder of 2020 compared with 2019, with Packaging likely to continue to experience higher demand, particularly for dispensing and closure products that help fight the spread of germs, while Specialty Products sales are expected to be lower than 2019 unless industrial activity begins to recover. We also expect our Aerospace segment's sales to further decline as compared to 2019, as customer orders are significantly lower than prior year as aircraft manufacturers slow or halt production in response to low demand for new planes following the onset of the COVID-19 pandemic. Although we have taken realignment actions to somewhat mitigate the impact of the lower demand levels, a clear picture for our business has yet to emerge, and we are unable to predict the full extent or duration of these impacts at this time.

We are continuing to manage production capacity to prevailing demand conditions where practical and have taken steps to reduce controllable costs. As we continue to navigate through this uncertain period, our goal will be to continue to mitigate the impact of lower volumes and execute strategic manufacturing footprint actions for our businesses experiencing decreased end-market demand, so we are positioned to gain operating leverage when certain end markets begin to recover. For those end markets where demand may increase, such as for our Packaging segment's dispensers and closures used in applications that help fight the spread of germs, improve personal hygiene, and advance home and industrial cleaning, we will continue to collaborate with our customers and strategic supply partners to ensure availability of capacity to fulfill requisite orders, while also investing in localizing supply where necessary.

As a result of continued uncertainties resulting from the COVID-19 pandemic, and their potential impact to our future results of operations, as well as to TriMas' market capitalization, we may record additional cash and non-cash charges related to further realignment actions, as well for uncollectible customer account balances, excess inventory and idle production equipment. At this time, we are not able to practically estimate the extent or amount of such potential cash and non-cash charges.

Despite the expected pressure to future demand levels and results of operations in our Aerospace and Specialty Products segments, at present, we believe our capital structure is in a solid position. We believe we have sufficient headroom under our financial covenants, and ample cash and available liquidity under our revolving credit facility, to meet our debt service, capital expenditure and other short-term and long-term obligations for the foreseeable future.

We expect to continue to leverage the tenets of the TriMas Business Model to address the ongoing challenges presented by the COVID-19 pandemic, and on a longer-term basis, achieve our growth plans, execute continuous improvement initiatives to offset inflationary pressures, and seek lower-cost sources for input costs, all while continuously assessing the appropriateness of our manufacturing footprint and fixed-cost structure.

### Impact of New Accounting Standards

See Note 2, "*New Accounting Pronouncements*," included in Part 1, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," within this quarterly report on Form 10-Q.

### Critical Accounting Policies

Certain of our accounting policies require the application of significant judgment by management in selecting the appropriate assumptions used in calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, our evaluation of business and macroeconomic trends, and information from other outside sources, as appropriate.

During the quarter ended June 30, 2020, the Company changed its accounting policy for asbestos-related matters, for which the new policy is described below.

### Asbestos-related Matters

We accrue loss reserves for asbestos-related matters based upon an estimate of the ultimate liability for claims incurred, whether reported or not, including an estimate of future settlement costs and costs to defend. We utilize known facts and historical trends for Company-specific and general market asbestos-related activity, as well as an actuarial valuation in determining estimated required reserves which we believe are probable and reasonably estimable. Asbestos-related accruals are assessed at each balance sheet date to determine if the liability remains reasonably stated. Accruals for asbestos-related matters are included in the consolidated balance sheet in “Accrued liabilities” and “Other long-term liabilities.”

Other than for the accounting policy for asbestos-related matters, there were no material changes to the items that we disclosed as our critical accounting policies in Part II, Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*," in the Annual Report on Form 10-K for the year ended December 31, 2019.

## Market risk

As filed, 650 characters.

In the normal course of business, we are exposed to market risk associated with fluctuations in foreign currency exchange rates. We are also subject to interest risk as it relates to long-term debt. See Part I, Item 2, "*Management's Discussion and Analysis of Financial Condition and Results of Operations,*" for details about our primary market risks, and the objectives and strategies used to manage these risks. Also see Note 11, "*Long-term Debt*," and Note 12, "*Derivative Instruments*," in Part I, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," included within this quarterly report on Form 10-Q for additional information.

## Controls and procedures

As filed, 2,097 characters.

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

### Evaluation of disclosure controls and procedures

As of September 30, 2020, an evaluation was carried out by management, with the participation of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) pursuant to Rule 13a-15 of the Exchange Act. The Company's disclosure controls and procedures are designed only to provide reasonable assurance that they will meet their objectives. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2020, the Company's disclosure controls and procedures are effective to provide reasonable assurance that they would meet their objectives.

### Changes in internal control over financial reporting

In response to the COVID-19 pandemic, we have required certain employees, some of whom are involved in the operation of our internal controls over financial reporting, to work from home. Despite this change, there have been no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls to minimize any impact it may have on their design and operating effectiveness.

## Risk factors

As filed, 4,474 characters.

The information set forth in this report, including without limitation, the risk factor presented below, updates and should be read in conjunction with, the risk factors and information disclosed in Part 1, Item 1A., "*Risk Factors*," in our Annual Report on Form 10-K for the year ended December 31, 2019.

***The novel coronavirus (COVID-19) pandemic has had, and is expected to continue to have, a significant impact on the Company's operations and results.***

Since late January 2020, we have been managing matters related to the global COVID-19 pandemic, including impacts to our operations and strategic supplier-partners in Asia, and, more recently, our manufacturing operations in Europe and North America. As a result of COVID-19, we have experienced temporary disruptions in the operation and workforce staffing of certain of our manufacturing facilities, as we were early adopters of many of the workplace guidelines recently published by the U.S. Centers for Disease Control and Prevention ("CDC") and took precautionary measures when necessary. COVID-19 has also affected our customers and suppliers, and we are collaborating with them to minimize supply chain disruptions. In response to the pandemic and related mitigation measures, we also implemented pandemic and business continuity plans, as well as other precautionary measures on behalf of our customers and employees, including supporting remote work opportunities for certain of our employees. While we believe that all these measures have been necessary or appropriate, they have resulted in additional costs and may adversely impact our business and financial performance in the future or expose us to additional unknown risks.

The COVID-19 pandemic has impacted our results of operations, and we expect it will continue to impact us in the future at varying levels. For example, due in part to the impact of the COVID-19 pandemic, sales for our dispensing and closure products increased, while sales in our Aerospace and Specialty Products segments decreased, in the second and third quarters of 2020. Although it is not possible to predict the ultimate impact of COVID-19, including on our business, results of operations, financial position or cash flows, such impacts that may be material include, but are not limited to: (i) shifting customer demand for many of our products, including those used in cosmetic, personal care, pharmaceutical, household product, food and beverage, and industrial markets, as well as aerospace markets; (ii) increased credit risk, including increased failure by customers experiencing business disruptions to make timely payments; (iii) reduced availability and productivity of employees, as well as increased costs associated with our high-deductible medical insurance plan if our employees become ill; (iv) increased operational risks as a result of manufacturing facility disruptions or remote work arrangements, including the potential effects on internal controls and procedures, as well as cybersecurity risks and increased vulnerability to security breaches, information technology disruptions and other similar events; (v) delays and disruptions in the availability of and timely delivery of materials and components used in our operations, as well as increased costs for such materials and components; (vi) customer requirements to accelerate the relocation of certain of our production lines to North America, which may increase our capital investment needs and launch costs; (vii) a negative impact on liquidity position; (viii) any impairment in value of tangible or intangible assets which could be recorded as a result of weaker economic conditions; and (ix) increased costs and less ability to access funds under our existing credit facility and the capital markets.

The extent of the COVID-19 pandemic's effect on our operational and financial performance will depend in large part on future developments, which cannot be predicted with confidence at this time. Future developments include the duration, scope and severity of the pandemic, the actions taken to contain or mitigate its impact, and the resumption of widespread economic activity. In addition, because we cannot predict the impact that COVID-19 will ultimately have, the actual impact may also exacerbate other risks discussed in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, any of which could have a material effect on us.

Filed Oct 29, 2020.
Source: SEC EDGAR, the filing index for accession 0000842633-20-000093. Last ingested by Listed: Nov 15, 2026, 01:26 ET. No prices; not investment advice.
